Merck KGaA said Wednesday that it has extended its collaboration with
Baylor College of Medicine in Houston to accelerate manufacturing of
Baylor’s Covid-19 vaccine candidates.
The German pharmaceuticals and chemicals company said the teams will
improve the manufacturing platform for the CoV RBD219-N1 vaccine
candidate and develop a new manufacturing platform for a second
candidate to accelerate the transition to phase-1 clinical trials.
“The goal for the partnership is to develop a manufacturing process
and steps that would lead to a scale-up approach suitable for pilot and
later industrial production,” it said.
https://www.marketscreener.com/MERCK-KGAA-436395/news/Merck-Baylor-College-to-Advance-Manufacturing-Platform-for-Covid-19-Vaccine-Candidates-30680670/
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.